化工儀器網(wǎng)>產(chǎn)品展廳>生命科學(xué)儀器>神經(jīng)生物學(xué)儀器>細(xì)胞/組織支持系統(tǒng)> B95-8轉(zhuǎn)化的絨猴白細(xì)胞、B
B95-8轉(zhuǎn)化的絨猴白細(xì)胞,、B
具體成交價(jià)以合同協(xié)議為準(zhǔn)
- 公司名稱 上海富雨生物科技有限公司
- 品牌
- 型號(hào)
- 產(chǎn)地
- 廠商性質(zhì) 生產(chǎn)廠家
- 更新時(shí)間 2025/2/12 10:02:49
- 訪問(wèn)次數(shù) 35
聯(lián)系方式:陳壽彬18956075901 查看聯(lián)系方式
聯(lián)系我們時(shí)請(qǐng)說(shuō)明是化工儀器網(wǎng)上看到的信息,,謝謝!
產(chǎn)品名稱:B95-8轉(zhuǎn)化的絨猴白細(xì)胞,、B95-8轉(zhuǎn)化的絨猴白細(xì)胞、B95-8轉(zhuǎn)化的絨猴白細(xì)胞,、B95-8轉(zhuǎn)化的絨猴白細(xì)胞,;細(xì)胞介紹 B95-8細(xì)胞株源自暴露于人白血球中抽提的EB病毒的絨猴白血球。B95-8是一個(gè)連續(xù)株并釋放高滴度的轉(zhuǎn)染EB病毒,。此細(xì)胞株提供EB病毒用于建立人的連續(xù)淋巴細(xì)胞株,。 細(xì)胞特性 1) 來(lái)源:外周血淋巴細(xì)胞 2) 形態(tài):淋巴母細(xì)胞樣,懸浮生長(zhǎng) 3) 含量:>1x106 個(gè)/mL 4) 污染:支原體,、細(xì)菌,、酵母和真菌檢測(cè)為陰性 5) 規(guī)格:T25瓶或者1mL凍存管包裝 運(yùn)輸和保存 可選擇干冰運(yùn)輸及發(fā)送復(fù)蘇存活細(xì)胞方式 (1)干冰運(yùn)輸,收到后立即轉(zhuǎn)入液氮或者-80度冰箱凍存或直接復(fù)蘇,; (2)存活細(xì)胞,,收到后應(yīng)繼續(xù)生長(zhǎng),傳代達(dá)到細(xì)胞生長(zhǎng)狀態(tài)良好時(shí),,再進(jìn)行凍存,。具體操作見細(xì)胞培養(yǎng)步驟。 (3)收到細(xì)胞后請(qǐng)拍照,,3天內(nèi)如果發(fā)現(xiàn)污染,,請(qǐng)及時(shí)拍照與我們聯(lián)系。 細(xì)胞用途 :僅供科研使用,。 細(xì)胞接收后的處理: 1) 收到細(xì)胞后,,請(qǐng)檢查發(fā)貨培養(yǎng)瓶的狀況,若發(fā)現(xiàn)培養(yǎng)瓶破損,、有液溢出及細(xì)胞有污染,,請(qǐng)拍照后及時(shí)聯(lián)系我們。 2) 在顯微鏡下確認(rèn)細(xì)胞生長(zhǎng)狀態(tài)時(shí),,在低倍鏡(4或5X物鏡)下進(jìn)行,,能準(zhǔn)確判斷細(xì)胞的傳代密度??醇?xì)胞的形態(tài)請(qǐng)?jiān)?0X和20×物鏡下,,同時(shí)給剛收到的細(xì)胞拍照,(10×,,20×)各2-3張以及培養(yǎng)瓶外觀照片一張留存,,作為細(xì)胞需要售后時(shí)提供收到細(xì)胞時(shí)細(xì)胞狀態(tài)的依據(jù)。 3) 觀察好細(xì)胞狀態(tài)后,,75%酒精消毒瓶壁將T25瓶置于37℃培養(yǎng)箱放置約2-3h,。 4) 貼壁細(xì)胞:在運(yùn)輸過(guò)程中貼壁細(xì)胞會(huì)有脫落的現(xiàn)象,,如發(fā)現(xiàn)貼壁細(xì)胞有脫落或者脫落后抱團(tuán)生長(zhǎng),可將T25瓶置于37℃培養(yǎng)箱放置約2-3h,,然后抽出瓶中的培養(yǎng)基和未貼壁細(xì)胞1000rpm離心5分鐘,,棄去上清重懸后接種到加有按照說(shuō)明書細(xì)胞培養(yǎng)條件新配制的培養(yǎng)基的原培養(yǎng)瓶中(或新的培養(yǎng)瓶中)。
cardiovascular side effects. One such new form of treatment is immune checkpoint inhibitor (ICI) therapy, which is regarded as the most important oncological milestone of the last decade due to its excellent oncological ewdtcacy; however, the growing use has revealed a high risk of diverse cardiovascular side effects with high morbidity and mortality, so that cardio-oncological care of affected patients is of particular importance. This review summarizes the current scientific and clinical state of the pathophysiology, incidence, diagnosis and treatment of cardiovascular side
cardiovascular side effects. One such new form of treatment is immune checkpoint inhibitor (ICI) therapy, which is regarded as the most important oncological milestone of the last decade due to its excellent oncological ewdtcacy; however, the growing use has revealed a high risk of diverse cardiovascular side effects with high morbidity and mortality, so that cardio-oncological care of affected patients is of particular importance. This review summarizes the current scientific and clinical state of the pathophysiology, incidence, diagnosis and treatment of cardiovascular side